Brachytherapy Market Updates

Brachytherapy Market size was valued at USD 539.61 Million in 2023 and is poised to grow from USD 582.24 Million in 2024 to USD 1069.72 Million by 2032, growing at a CAGR of 7.9% during the forecast period (2025-2032).

The global brachytherapy market is highly competitive, with several key players competing for market share. These companies focus on developing advanced brachytherapy technologies, expanding their product portfolios, and expanding their presence in emerging markets. 'Eckert & Ziegler BEBIG (Germany)', 'Varian Medical Systems, Inc. (United States)', 'Elekta AB (Sweden)', 'IsoAid LLC (United States)', 'Theragenics Corporation (United States)', 'C. R. Bard, Inc. (United States)', 'Boston Scientific Corporation (United States)', 'Isoray Inc. (United States)', 'Nucletron B.V. (Netherlands)', 'Huiheng Medical, Inc. (China)', 'iCAD, Inc. (United States)', 'Elekta AB (Sweden)', 'Nanobiotix SA (France)', 'BTG International Ltd. (United Kingdom)', 'GE Healthcare (United States)', 'IBA Worldwide (Belgium)', 'Cianna Medical, Inc. (United States)', 'Theragenics Corporation (United States)', 'C4 Imaging LLC (United States)', 'CIVCO Medical Solutions (United States)', 'RaySearch Laboratories AB (Sweden)', 'Hologic, Inc. (United States)'

Minimally invasive treatment procedures are preferred by patients due to reduced post-operative complications, shorter hospital stays, and faster recovery times. Brachytherapy is a minimally invasive treatment option that can be performed on an outpatient basis in many cases. The increasing demand for minimally invasive procedures contributes to the growth of the brachytherapy market.

Growing preference for organ-preserving treatments : Brachytherapy is often chosen as an organ-preserving treatment modality, particularly in cancers such as prostate, breast, and cervical cancer. It allows for targeted radiation delivery while minimizing damage to surrounding healthy tissues, thereby preserving organ function and improving quality of life for patients. The trend towards organ preservation and minimally invasive treatments has led to increased adoption of brachytherapy.

With a 45.7% revenue share in 2023, North America dominated the brachytherapy market. Due to the benefits, it provides over conventional methods—namely, that it is a relatively safer and effective cancer treatment—brachytherapy is commonly utilized in North America. In 2022, Europe represented a share of almost 25,0%. Over the past five years, brachytherapy use in the European region has grown.